Abstract 2676
Background
Oncology nurses are responsible to provide their patients with the evidence-based care. Clinical guidelines or recommendations can be developed by scientific associations as a guide for performing evidence-based practice. These guidelines are often taken into consideration for the assessment of professional responsibility, as well as to guide the practice. The Italian Institute of Health identified the Italian Association of Cancer Nurses (AIIAO) among the scientific societies authorised to produce, adapt and implement guidelines. However, it is important to identify which areas of oncology nursing warrant an action to facilitate AIIAO in setting the agenda. A specific prerequisite for developing high-quality guidelines is incorporating nurses’ views into priority-setting. The aim of this study is to use a bottom-up approach to empirically investigate which areas of oncology nursing require higher priority in the definition of evidence-based recommendations.
Methods
This is a multi-phase study including a cross-sectional national survey. In order to develop the tool for the survey, a systematic search of the literature, a focus group, and content and face validity evaluation will be conducted.
Results
Seven areas were identified by the literature review to develop the survey: (a) fatigue; (b) pain; (c) sleep disorders; (d) secondary symptoms; (e) cognitive impairment resulting from cancer and its treatment; (f) chemotherapy-induced peripheral neuropathy; and (g) psychological distress. This research is still ongoing. A panel of researchers are operationalising the identified areas in the items for the national survey. Cancer nurses will be asked to rate the priority of each area for the implementation, adaptation and development of AIIAO clinical guidelines.
Conclusions
The results of this survey might raise awareness about oncology nurses’ opinions on which areas of clinical practice warrant an action. This will facilitate the associations and affiliated working groups in developing evidence-based recommendations. Moreover, a bottom-up mapping of the nurses’ priorities will inform the planning of AIIAO strategic activities targeted to strengthen cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Italian Association of Cancer Nurses (AIIAO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract